Franco Borzio's research while affiliated with Azienda Ospedaliera Fatebenefratelli e Oftalmico Milano and other places

... Our study demonstrated that hepatic resection or radiofrequency or microwave ablation might be the best choice of intermediate-stage HCC receiving TACE as first-line treatment based on 3-year predicted survival. This result ties well with previous studies that whenever possible, potentially curative treatments should be preferred to TACE repetition in case of non-response or at the time of cancer recurrence after the first TACE treatment since the survival of HCC patients is largely determined by the more effective treatment received, irrespective of the therapeutic sequence adopted [38,39]. We speculate that this might be due to the strict indication and contraindication [19] of these treatments. ...

... Therefore, it was not surprising that, after a first-line TACE, the adoption of treatment that can provide a higher survival benefit was associated with a better prognosis [38]. Moreover, it has already been demonstrated that surgical treatment of HCC recurrence is a favorable prognostic factor [40][41][42]. Therefore, the principle of first considering the therapy with the highest survival benefit is also valid in the second-line setting in case of non-response or recurrence after the frontline therapy [43]. Although, we lacked information on molecularly targeted agents and immune checkpoint inhibitors due to the retrospective study. ...

... However, for patients with diagnosed HCC, the influence of MetS on their survival remains unclear (18). Some previous studies showed that MetS may be a risk factor of poor survival of patients with HCC (19)(20)(21)(22)(23), while other studies did not show similar results (24)(25)(26)(27)(28). In this study, we performed a systematic review and metaanalysis to comprehensively investigate the association between MetS and survival of patients with HCC. ...

... In recent years, there has been a growing interest in studies on TBS in PLC, making it a clinical research hotspot. The TBS model has demonstrated its prognostic risk stratification capabilities in hepatocellular carcinoma (HCC) [20], ICC [21], and combined hepatocellular − cholangiocarcinoma [22], while remaining user − friendly. Relevant studies have shown a strong correlation between radiological TBS and pathological TBS, with no significant difference observed in postoperative prediction ability [23,24]. ...

... In our cohort, nivolumab showed a longer OS compared to sorafenib, despite the presence of multiple negative confounders, such as the presence of more co-morbidities, more patients with ECOG 2 status, BCLC C status, extravascular invasion, and CTP B status in the nivolumab arm. In previous analyses of patients with uHCC, the CTP score, BCLC stage, and performance status have been prognostically valuable in predicting OS [20][21][22][23]. The survival of sorafenib-treated CTP B patients in our study (5 months) was comparable to real-life data reported from the GIDEON registry (5.2 months) [20]. ...

... The benefits of achieving SVR with hepatitis C antiviral therapy are well established. These benefits have been shown throughout each stage of fibrosis and also in patients with a history of HCC after curative treatment [17,18] and non-curative treatment [19] . A recently published multicentre USA retrospective study showed that the SVR is associated with a decreased risk of hepatic decompensation in patients with HCVrelated HCC who receive non-curative therapies [19] . ...

... 25,26 In HCV-related HCC, sustained viral eradication obtained by interferon-based or interferon-free regimens significantly reduces tumor recurrence without differences associated with the antiviral strategy used. 27 However, a meta-analysis showed that recurrence risk and survival were extremely variable in patients with successfully treated HCV-related HCC, providing a useful benchmark for indirect comparison of the benefits of directacting antivirals. 28 In addition, a high HBV load has been associated with poor RFS and OS in patients with HCC after hepatectomy. ...

... Notably, the survival benefit persisted even after correcting for baseline clinical characteristics using propensity score analysis. 38 Several other retrospective studies conducted mainly in Chinese cohorts also proved the benefit of liver resection over TACE in selected patients with intermediate-stage HCC. [39][40][41][42][43] Conversely, only two studies reported no difference between these treatments; Ciria et al. 44 showed no significant difference in the overall survival between patients with intermediate-stage HCC treated with LR and those treated with TACE in a cohort of 80 patients from Spain. ...

... In Italy, high HCC incidence and mortality rates have been highlighted, with a northto-south increasing gradient [15,18], as compared with other European and Western countries [19,20], with about 90% of primary liver neoplasm estimated to be attributable to HBV and HCV infections [21]. More recently, in Italy, a significant decrease in HCC incidence, together with an improvement in survival outcomes, was reported [22]. ...

... HCC is one of the main causes of tumor death in Italy and its therapeutic management is extremely complex due to its peculiarities compared to most solid tumors [2] . ...